Cancer stem cells are an attractive therapeutic target for cancer. The present study examined stem cell characteristics of CD133+ cells isolated from endometrial cancer. Phenotypic characteristics, proliferation, migration, anchorage-independent growth, chemoresistance, gene expression profile and tumorigenicity of CD133+ tumor cells were assessed. Primary tumor exhibited immunoreactivity for CD133. Endometrial CD133+ tumor cells enhanced proliferation rate, colony formation, chemotaxis migration ability, and chemoresistance to cisplatin, paclitaxel, and doxorubicin than CD133-cells. CD133+ cells expressed more cancer stem cells markers such as EpCAM, aldehyde dehydrogenase 1 and insulin-like growth factor-1 receptor than CD133-cells. Moreover, CD133+ cells also increased expression of embryonic stem cell markers including oct4, nanog, sox2, and cmyc than CD133-cells. Finally, CD133+ tumor cells could generate xenograft but not CD133-tumor cells. CD133 and Ki67 were extensively expressed in the xenograft. In conclusion, endometrial CD133+ tumor cells displayed cancer stem cell characteristics and might represent a valuable tool for identifying endometrial cancer stem cells and hence a potential therapeutic target.
Introduction
Endometrial cancer (EC) is the most common gynecologic pelvic malignancy in western countries, and its incidence is rising [1] . Endometrial cancer is usually diagnosed at an early stage due to initial presentation of abnormal vaginal bleeding. Approximately 80% of patients are diagnosed as having stage I disease; and 13%, as having stage 2 disease [2] . Although 88% of 5-year survival rate was noted in stage 1 disease, subgroups of patients have decreased survival rate [2] . Various prognostic factors, such as tumor grade, histologic type, high-grade lesions and deep invasion of the uterus have been identified [1] . The recurrence risk of endometrial cancer depends on the presence or absence of specific prognostic factors [3] . According to the above findings, novel target therapies need to be developed [4] .
Cancer stem cells (CSCs) have been identified in leukemia and several solid tumors [5] [6] [7] . CSCs have self-renewal activity, produce progeny cells, constitute a small minority of neoplastic cells within a tumor, and possess the developmental potential for expression of multiple specific markers [8] . CSCs are also resistant to current cancer treatment, resulting in recurrence.
CD133 is a 120-kDa glycoprotein and a member of the family of pentaspan membrane glycoproteins [9] . CD133 can express in hematopoietic stem cells
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International Publisher from adult blood, bone marrow and umbilical cord blood and on endothelial, neural and epithelial cells [10] [11] [12] . CD133 have been found in CSCs from prostate [13] , lung [14] , brain [15] , colon [16, 17] , and ovarian cancer [18] and acute lymphoblastic leukemia [19] . CD133 has been detected by its glycosylated epitope, AC133, consistent with the knowledge that the glycosylation state of a cell changes upon malignant transformation. CD133+ cells isolated from human endometrium show a low colony-forming unit capacity [20] . Whether endometrial cancer-isolated CD133+ cells possess CSC characteristics remains to be further clarified.
The present study was designed with the aim to determine CD133 expression in human endometrial cancer cells and to examine its self-renewal ability and chemoresistance. Gene expression and tumorigenicity of endometrial CD133+ tumor cells were also investigated.
Materials and methods

Patient characteristics
CD133+ and CD133-cells were isolated from tumor tissue specimen at the time of primary surgery from a 58-year-old woman with stage IA, grade 1 endometrioid adenocarcinoma of the endometrium (EC). She received laparoscopic staging surgery in 2010 and regular followed up without recurrence. Written informed consent to tumor tissue collection and its use for isolation of putative tumor stem cells was obtained from the patient according to the research protocol approved by the Research Ethics Committee of Buddhist Tzu Chi General Hospital (IRB 097-111).
Tissue collection, isolation and culture of CD133+ cancer cells
At the time of tissue collection, the tumor specimen was cut into two halves; one-half for confirming the pathological diagnosis, and the other half for isolation, purification, and culture of CD1333+ and CD133-cells. Within 30 min from surgery, tumors were mechanically and enzymatically dissociated with trypsin-EDTA for 15 min and then with collagenase I for 3 h at 37 o C.
Cell suspensions were incubated with ammonium chloride (StemCell Technologies, Vancouver, British Colombia, Canada) for 10 min at 4 o C to remove red blood cells. The CD45 MicroBeads (Miltenyi Biotec, Bergish Gladbach, Germany) was used for negative selection of non-hemopoietic CD45-cells. Then followed by positive selection of CD133+ cells were made using an AutoMACS platform (Miltenyi Biotec, Bergish Gladbach, Germany). The counterparts after CD133+ cells selection were designed as CD133-cells. The purity of selected CD133 population was assessed by flowcytometry of the expression of CD133 and CD45 (BD, PharMingen, Franklin Lakes, NJ, USA). Isolated CD133+ and CD133-cells were maintained in RPMI-1640 culture medium (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS, Biological Industries, Kibbutz, Israel).
The specimen of normal endometrium (n=1) and the endometrium near the cancer part (n=1) were also dissected for the experiment and maintained in DMEM-low glucose medium (LG, Gibco, Grand Island, NY, USA) supplemented with 10% FBS. Endometrial cancer tissue was also sent to immunohistochemical (IHC) staining with CD133 (Miltenyi Biotec, Bergish Gladbach, Germany) and cytokeratin-7 (CK7, Bioss Inc., Woburn, MA, USA). Cell nuclei were stained with DAPI (4',6-diamidino-2-phenylindole, Sigma, St Louis, MO, USA).
Cell proliferation assay
Cell proliferation assays were performed by plating CD133+ and CD133-cells in T25 flasks with RPMI 1640 supplemented with 10% FBS at a density of 90,000 cells/ml. Cell counts were obtained on days 0, 3, 6, 8, and 10 using XTT assay (Roche, Mannheim, Germany) following the manufacturer's protocol. Each experiment was performed in triplicate.
Chemotaxis migration assay
CD133+, CD133-cancer cells, and RL95-2 cells (used as the control cell line) were seeded in the upper well of a 24-well transwell Boyden chamber (8 μm pore size; Costar, Corning Inc., Corning, NY, USA) and allowed to migrate towards cell-free media derived from ovarian stromal cells and follicular fluid (FF) placed in the bottom of wells. Cell growth medium was used as the control medium. Migration was assessed 48 hours later. The migrated cells were stained with crystal violet (Sigma-Aldrich, St Louis, MO, USA) and counted using bright-field microscopy. Each experiment was performed in triplicate.
RL95-2 cell is an endometrial cancer cell line obtained from BCRC (Bioresource Collection and Research Center, Hsinchu, Taiwan). The culture medium for RL95-2 was composed of 90% of a 1:1 ratio mixture of DMEM and Ham's F12 medium with 10 mM HEPES, 5 ug/ml bovine insulin, 2 g/L sodium bicarbonate, and 10% fetal bovine serum. Dr. Chu's lab provided primary ovarian stromal cells (obtained from ovarian specimen) and FF (obtained from oocyte retrieval). The ovarian stromal cell-conditioned medium was collected for 48 h by incubating ovarian stromal cells with high-glucose DMEM (Gibco, Grand Island, NY, USA) further supplemented with 10% FBS and 1% penicillin/streptomycin.
Anchorage-independent growth (AIG)
The soft agar assay for anchorage-independent growth was carried out on 5×10 5 CD133+ and CD133-cells in growth medium (4 ml) supplemented with 0.35% agarose and layered on a 5 ml base of 0.7% agarose. After 14 days, the cells were stained with 0.8 mM crystal violet (Sigma-Aldrich, St. Louis, MO, USA). The colonies larger than 30 μm were counted using bright-field microscopy. Each experiment was conducted in triplicate.
Immunocytochemistry
CD133+ and CD133-cells were sequentially treated with commercially available fixation and permeabilization media (Sigma, St. Louis, MO, USA), followed by incubation for 1 h at 4 o C with monoclonal antibodies reacting against EpCAM (DakoCytomation, Glostrup, Denmark). FITC-conjugated goat anti-mouse antibodies were used as secondary reagents. Cell nuclei were stained with DAPI (Sigma, St. Louis, MO, USA).
Confocal microscopy
Serial
formalin-fixed, paraffin-embedded endometrial tumor samples were deparaffinized with xylene, followed by absolute ethanol, 95% ethanol, and distilled water. CD133 was visualized with a PE or FITC conjugated mouse anti-CD133 antibody (1:30 dilution, Miltenyi Biotec, Bergish Gladbach, Germany). K7 was visualized with an FITC conjugated rabbit anti-cytokeratin 7 antibody (Bioss Inc., Woburn, MA, USA). Cell nuclei were stained with DAPI (Sigma). Imaging was performed using two-photon absorption fluorescence. A conventional confocal laser-scanning microscope (LSM 510 META, Zeiss, Jena, Germany) was used for two-photon absorption. Colocalization was done using SV1 software (Scientific Volume Imaging, Hilversum, Netherlands).
Quantitative RT-PCR
Total RNA was extracted using RNEasy® (Qiagen, Venlo, Netherlands) according to the manufacturer's instructions. Real-time PCR analysis of candidate genes (CSC-related genes: ALDH1, IGF-1R, PDGFRA, and PDGFRB; embryonic stem cell-related genes: oct4, nanog, sox2, and cmyc; primer sequences listed in Table 1 ) was performed following the methods in previous reports [21, 22] . Briefly, complementary DNA was synthesized using a SuperScript III One-Step RT-PCR kit (Invitrogen, Grand Island, NY, USA) and amplified by PCR with an AmpliTaq Gold Kit (Applied Biosystems, Foster City, CA, USA). Real-time PCRs were performed and monitored using FastStart Universal SYBR green Master (ROX, Roche, Indianapolis, IN, USA) and a quantitative real-time PCR detection system (ABI Step One Plus system, Applied Biosystems, Foster City, CA, USA). The gene products were analyzed with the GAPDH gene as a reference. The expression level of each target gene was then calculated as 2 −ΔΔ Ct , as previously described [22] . Three readings of each experimental sample were obtained for each gene of interest and the experiments were repeated at least three times. In vitro sensitivity of endometrial CD133+/-cells to chemotherapeutic agents Dissociated CD133+ and CD133-cells were cultured for 48 h in the presence of escalating concentrations of cisplatin (0-15 μM, Abiplatin, ABIC LTD., NETANYA, ISRAEL), doxorubicin (0-65 μM, Adriblastina, Pfizer, Kent, NJ, USA) and paclitaxel (0-80 nM, Formoxol, Yung Shin Pharm. IND., Co. Ltd., Taichung, Taiwan) as detailed in the figure legends. Cell viability was determined using trypan blue exclusion and counted using XTT assay and presented as the percentage of no-treatment control.
Xenograft experiment of endometrial CD133+/-cells
The procedures for animal experiments were carried out in adherence to the National Institutes Health Guide for the Care and Use of Laboratory Animals approved by The Animal Research and Care Committee of the Buddhist Tzu Chi General Hospital.
Five-week-old Non-obese, diabetic-severe combined immune deficiency (NOD-SCID) (strain name: NOD.CB17-Prkdcscid/JTcu) mice were obtained from Tzu Chi University.
Isolated CD133+ and CD133-tumor cells (1.5 × 10 5 cells each 0.5 ml of medium per mouse, n = 3 in each group) were injected subcutaneously to examine the tumorigenesis. Mice were sacrificed 12 weeks after injection. The occurrence of tumor and tumor weight were measured. Tumor tissues were sent for histological examination. Hematoxylin and eosin staining and immunohistochemical analysis of CD133, CK7, and Ki67 was performed with staining with the specific antibody (BD Phamargen, San Diego, CA, USA). Tumor tissue was assessed at ×200 to ×400 total magnification.
Flowcytometry
The xenografted tumor were washed, acutely dissociated in DMEM and subject to enzymatic dissociation using 2 mM EDTA in PBS, washed with PBS containing 2% bovine serum albumin (BSA) and 0.1% sodium azide (Sigma, St Louis, MO, USA) and incubated with the anti-CD133 antibodies conjugated with FITC (BD, PharMingen, Franklin Lakes, NJ, USA). The cells were analyzed using a Becton Dickinson flow cytometer (Becton Dickinson, San Jose, CA, USA).
Statistical analysis
For data of in vitro and in vivo experiments, statistical comparisons among groups were performed using the Student's t-test or ANOVA with Bonferroni corrections. Differences between groups were considered statistically significant at p < 0.05. Data were expressed as mean ± SD.
Results
CD133 expressed diffusely in primary endometrial tumors
To examine CD133 expression in primary EC, IHC, flow cytometry and qPCR of cancer tissue were performed. IHC revealed tumor sections diffusely stained by anti-CD133 antibodies and K7 (Fig. 1A) . The tumor sample exhibited immunoreactivity with CD133 antibodies, which is in agreement with previously published reports on the phenotype of putative CSC in solid tumors [15] . Flow cytometry revealed 12.15% of CD133 expressed in freshly dissociated tumor cells (Fig. 1B) . Finally, quantitative mRNA signals for CD133 were detected in dissociated tumor samples (cancer and near-cancer parts), but not expressed in normal endometrial tissue (p < 0.001, Fig.  1C ). In summary, the results showed CD133 expression in EC epithelium.
Enhanced proliferation and chemotaxis migration of CD133+ endometrial tumor cells
To investigate characteristics of CD133+ tumor cells, their proliferation and chemotaxis migration capabilities were compared with CD133-tumor cells. As seen in the morphology of CD133+/-tumor cells shown in Fig. 2A Fig. 2B ).
Endometrial cancers are sometimes metastasis to the fallopian tube and ovary [23] . During ovulation, FF accompanied with oocytes extruded from a follicle, at the same time, ovarian stroma may increase exposure. Therefore, FF and condition medium (CM) from ovarian stromal cells were employed to investigate these chemotactic effects. Significantly enhanced migration of CD133+ cells towards FF compared with CD133-cells was observed (p < 0.05, Fig. 2C ) but not in RL95-2 cells. In FF, the migration of tumor cells, whether CD133+/-cells, was better than that of the control group. In CM of ovarian stroma cells, the migration ability of CD133+ tumor cells was also significantly better than that of CD133-cells (p < 0.05, Fig. 2D ). There was a significant enhancement in cell proliferation and migration of CD133+ cells than CD133-cells.
Enhancement in AIG of CD133+ than CD133-cells
The present results showed increase of AIG in soft agar colony assay, an important feature of tumor stem cells [24] , in CD133+ (Fig. 3A) than CD133-cells (Fig. 3B) . Quantification of colony number in soft agar showed more colonies noted in CD133+ cells than CD133-cells (Fig. 3C ).
Increased EpCAM expression in CD133+ cells
To investigate EpCAM (expressed in cancer stem cells of breast and colon [17, 25] ) expression in CD133+/-cells, IHC was used for evaluation. IHC revealed significantly more EpCAM-expressing cells in CD133+ cells than in CD133-cells (p < 0.01, Fig. 4) . 
Tumor-derived CD133+ cells expressed cancer and embryonic stem cell markers
To further understand the molecular events underlying CD133+ cells as CSC, the expression of genes related to the CSC such as ALDH1 (highly expressed in CSC) [26] [27] [28] [29] [30] and IGF-1R (hyperinsulinemia, risk factor of EC) [31] were examined by real-time PCR. The mRNA expression of these genes, including ALDH1 and IGF-1R were significantly upregulated in CD133+ cells compared with CD133-cells (Fig. 5A, B) . Nevertheless, there was no significant difference in expression of gene-related migration toward CM and FF, PDGFRA and PDGFRB [32] between the two groups of cells (Fig. 5C, D) .
Due to common stemness regulators between embryonic and cancer stem cells [33] , the pluripotent gene expressions of oct4, nanog, sox2, and cmyc in CD133+/-cells were investigated. This study found significantly increased the expression of oct4, nanog, sox2, and cmyc were noted in CD133+ cell than CD133-cells (p<0.001, Fig. 6 ).
Taken together, the findings revealed that CD133+ cells expressed more CSC-and ESC-related genes than CD133-cells.
Tumor-derived CD133+ cells had higher chemoresistance than CD133-cells
Tumor chemoresistance often comes from CSC with the characteristics of dormant and low proteasome activity [34] . To investigate the chemoresistance of EC-derived CD133+ and CD133-cells, both cells were exposed to increasing concentrations of chemotherapeutic drugs currently in use at the clinical setting, such as cisplatin, doxorubicin, and paclitaxel. As shown in Fig. 7 , all chemo drugs induced less cell death in CD133+ cells than CD133-cells, indicating that CD133+ cells harbored more resistance to chemotherapeutic agents.
In Fig. 7C , doxorubicin was unable to kill CD133+ cells on the high concentration of 65 μM, but CD133-cells had already died at the same concentration. That is why taxane-based therapy now becoming the first choice in the first-line and salvage settings of endometrial cancer [35] .
CD133+ tumor cells could generate xenograft tumor
To further explore the role of CD133+ tumor cells, 1.5 × 10 5 cells were injected into the subcutaneous region of six female NOD-SCID mice.
Three mice were injected with CD133+ cells and the other three mice were injected with CD133-cells. Tumor weight was evaluated after 12 weeks. CD133+ tumor cells could generate xenograft (3/3, Fig. 8A ) but not CD133-cells (0/3) (p < 0.001, Fig. 8B) . Moreover, the xenograft cells constantly expressed CD133 markers (93%, Fig. 8C ). The expression of CD133, Ki67 (proliferation marker) and CK7 (specific to mullerian origin of epithelium, used for comparison) were examined using IHC. Tumor histology stained by H & E staining, as shown in Fig.  8D , revealed undifferentiated EC. The xenografted tumor intensively express CD133, Ki67, and CK7, suggesting tumor proliferative activities (Fig. 8E) . Taken together, these results are consistent with the findings from the in vitro experiments and strongly support that CD133 as a cancer stem cell marker in EC. 
Discussion
Novel target therapies are required for EC in addition to conventional therapy. Nevertheless, the current therapeutic strategies to target CSCs do not yield satisfactory results [36] . Several CSC markers such as CD133, CD44, and CD117 have been observed in EC and ovarian cancer [37] [38] [39] [40] [41] [42] [43] [44] , and the CSC population in EC has been reported to range from 1.3 to 62.6 % [38] . Other than EC, CSC has been reported at less than 1% of hematological malignancies, in which CSC have been well studied [36] . However, the discrepancy in EC population indicates that the targetable characteristics of CSCs need to be further confirmed. The present study investigated the various characteristics of the CD133+ population in EC. The CD133+ cells possessed more migratory capability than CD133-cells. Enhanced EpCAM expression was also observed in CD133+ tumor cells. More CD133+ cells expressed CSC-related genes like ALDH1 and IGF-1R and also embryonic stem cells genes oct4, nanog, sox2, and cmyc. CD133+ cells also harbored more chemoresistance and tumorigenesis capability. Enhanced CD133 and Ki67 expressions were noted in xenograft. We compared the current study with the previous reports in Table 2 .
Criteria for defining CSC included self-renewal, restriction to a minority of the total tumor population, reproducible tumor phenotype, multipotent differentiation, and expression of unique cell surface markers, and consistent isolation [45] . CD133 may serve as a marker of tumor-initiating cells in a variety of human cancers, making it a good candidate for target therapy [9] . The present study found endometrial cancer cells mainly expressed the CD133+ cells, and CD133+ tumor cells were capable of self-renewal and forming larger colonies under appropriate culture conditions.
In this study and a previous report, proliferation rate was found to be more rapid in CD133+ cells than CD133-cells [38] .
Chemotaxis is a basic biological process in which a cell migrates following the direction of a spatial cue. A form of a gradient of chemoattractants provided the spatial cue [46] . Migration ability is taken as one of the mechanisms behind metastasis; hence, it is essential to understand the capacity of CSCs to migrate to other tissues using in vitro migration assay. In this experiment, CD133+ cells showed a higher migration potential than CD133-cells under the stimulation of FF and CM of ovarian stromal cells. While the migration capacity of tumor cells is under the control of a large range of receptors and chemokines, further in vitro and in vivo studies are required to address this property fully. The gene expression of PDGFR, the receptor of PDGFA and PDGFB that are rich in FF and CM [32] were explored, but no significant difference in PDGFRA and PDGFRB expressions between CD133+ and CD133-cells was found. Regarding which gene affects the migration capability needs further investigation. When assessing the current CSC-associated gene expression profile of CD133+ cells compared with CD133-cells, CD133+ cells preferentially expressed EpCAM (highly expressed in serous uterine carcinoma) [47] , aldh1 (highly expressed in CSC) [26] [27] [28] [29] [30] and IGF-1R (hyperinsulinemia, a risk factor of EC) [31] . Cancer usually shared the common stemness regulators of embryonic stem (ES) cells [33] . The CD133+ cells also increased expression the oct4, nanog, sox2, and cmyc, the same stemness genes in ES cells. These results indicated that gene expression profile of CD133+ cells was different from that of CD133-cells.
Therapeutic resistance is a key fundamental feature of CSCs. In the treatment of EC, cisplatin, paclitaxel and doxorubicin and radiation therapy are important [48] . The current results indicate that tumor-derived CD133+ cells have significant resistance to cisplatin, paclitaxel and doxorubicin in vitro when compared with their negative counterparts.
The possibility of obtaining a virtually unlimited number of CD133-derived endometrial tumor cells has potential implications for the in vitro evaluation of drug sensitivity, and the availability of cells closely resembling the original tumor will allow the identification of novel drugs for individualized anticancer therapies.
The definition of CSC ultimately depends on in vivo xenograft experiments. It was found that CD133+ cells could grow tumors in all three xenografted NOD-SCID mice with 1.5 × 10 5 cells but not CD133-cells. This finding is consistent with previous reports on colon cancer [49] and glioblastoma multiforme [50] . CSCs were found in CD133+ fractions of EC. However, CD133-fractions could not form the xenograft in this experiment, which is inconsistent with previous findings [38] . The discrepancy may be caused by insufficient time to grow CD133-cells in mice (3 months in this experiment). The xenografted tumor could also enrich CD133+ fractions of tumor cells and recapitulated the original histology of the primary tumor [38] .
The limitation of this study is as type I endometrial carcinomas account for more than 90% of endometrial cancers, the CD133 cells used in this study may not well represent the genetic profile, clinical presentation, and prognosis of the dominant type (carcinoma) of the endometrial cancers.
In conclusion, CD133+ cells can be isolated from human EC, can extensively propagate and migrate in vitro, exhibit chemoresistance and generate xenograft. CD133+ cells showed CSC markers such as EpCAM, aldh1, and IGF1R and ES cells markers including oct4, nanog, sox2, and cmyc. CD133 that exhibit stem cells characteristics [25] is a potentially useful antigen for the identification of EC stem cells and can be used for future target therapy [51] .
